Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025

(TheNewswire)

Toronto, Ontario – TheNewswire- 15 December, 2025 – Helix BioPharma Corp.(TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” )( “Helix” or the “Company” ), a clinical-stage oncologycompany shaping a near future where today’s hard-to-treat cancersare vincible, announces the filing of theCompany’s unaudited interim financial statements as of and for thethree month period ended October 31, 2025 (the “Financial Statements” ), the management’s discussion and analysis ( “MD&A” ), andthe certifications of the Chief Executive Officer and Chief FinancialOfficer (respectively, “CEO” and “CFO” ) relatingto the Financial Statements (collectively, the “Interim Filings” ). The Interim Filings are available on the Company’sprofile at www.sedarplus.ca and on its websiteat https://www.helixbiopharma.com/filings-and-financials/ .

About Helix BioPharma

Helix BioPharma is an oncology company that innovatesfrom strength to bring near-term solutions for today’shardest-to-treat cancers. The Company’s pipeline is led by TumorDefense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugatedesigned to prime CEACAM6-expressing tumors for increased sensitivityto therapy and augment the effectiveness of today’s front-runninganti-cancer treatments. L-DOS47 has completed Phase Ib studies innon-small cell lung cancer (NSCLC) and shares its CEACAM6-targetingfoundation with Helix’s next-generation bi-specific antibody-drugconjugates (ADCs), currently in discovery. The Company also advancestwo pre-IND candidates: (i) LEUMUNA™, an oral immune checkpointmodulator aimed at achieving durable remission in post-transplantleukemia relapse, and (ii) GEMCEDA™, a first-in-class oralgemcitabine prodrug with bioavailability on a par with IV, designed toexpand treatment options for advanced cancers.

Helix is listed on TSX (HBP), OTC PINK (HBPCD), and FWB(HBP0). For more information, pleasevisit : https://www.helixbiopharma.com/

For more information, pleasecontact:

Helix BioPharma Corp.

Bay Adelaide Centre - North Tower

40 Temperance Street, Suite 2700

Toronto, ON M5H 0B4

Tel: +1 857 208 7687

Jacek Antas, Director

corporate@helixbiopharma.com

Forward-Looking Statements and Risksand Uncertainties

This news release containsforward-looking statements and information (collectively,“forward-looking statements”) within the meaning of applicableCanadian securities laws. Forward-looking statements are statementsand information that are not historical facts but instead includefinancial projections and estimates, statements regarding plans,goals, objectives, intentions and expectations with respect to theCompany’s future business, operations, research and development,including the Company’s activities relating to DOS47, LR 09 andGEMCEDA. Forward- lookingstatements can further be identified by the use of forward-lookingterminology such as “ongoing”, “estimates”, “expects”, orthe negative thereof or any other variations thereon or comparableterminology referring to future events or results, or that events orconditions “will”, “may”, “could”, or “should” occuror be achieved, or comparable terminology referring to future eventsor results.

Forward-looking statements arenecessarily based on a number of estimates and assumptions that theCompany considered appropriate and reasonable as of the date suchinformation is given, including but not limited to the assumptionsregarding the implied benefits of the transactions. Forward-lookingstatements are subject to known and unknown risks, uncertainties, andother factors, many of which are beyond the Company’s control, thatmay cause actual results, performance or achievements to be materiallydifferent from those expressed or implied by such forward-lookingstatements, including but not limited to the risk that theCompany's assumptions on which its forward-looking statements arebased may not be accurate; the ability of the Company to capitalize onthe potential benefits of the transactions; and the risk factorsdisclosed in the Company's periodic reports publicly filed andavailable on its SEDAR+ profile at www.sedarplus.ca . No assurance can be given that any ofthe events anticipated by the forward-looking statements willtranspire or occur. There is no assurance that the proposedtransactions will be completed in accordance with its terms or at all.The forward-looking statements contained in this news release are madeas of the date of this announcement and the Company does not assumeany obligation to update any forward-looking statement or informationshould those beliefs, assumptions, opinions or expectations, or othercircumstances change, except as required by law.

_________________

Copyright (c) 2025 TheNewswire - All rights reserved.